专题:Pharmacology and Obesity Treatment

This cluster of papers focuses on the pharmacological management of obesity, including the use of anti-obesity drugs, clinical trials evaluating their efficacy and safety, and the impact on weight loss. It covers a wide range of medications such as sibutramine, orlistat, and ephedra alkaloids, as well as their associated adverse events and lipase inhibitors.
最新文献
Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial

article Full Text OpenAlex

Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial

article Full Text OpenAlex

Genetic predictors of GLP1 receptor agonist weight loss and side effects

article Full Text OpenAlex

GLP-1 Receptor Agonists

review Full Text OpenAlex

Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial

article Full Text OpenAlex

Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial

article Full Text OpenAlex

The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications

review Full Text OpenAlex

Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression

review Full Text OpenAlex

Micronutrient and Nutritional Deficiencies Associated With GLP ‐1 Receptor Agonist Therapy: A Narrative Review

review Full Text OpenAlex

GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits

review Full Text OpenAlex

近5年高被引文献
Tirzepatide Once Weekly for the Treatment of Obesity

article Full Text OpenAlex 3811 FWCI383.0989

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

article Full Text OpenAlex 3217 FWCI660.8363

Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

article Full Text OpenAlex 1168 FWCI181.8792

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

article Full Text OpenAlex 1116 FWCI107.8075

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes

article Full Text OpenAlex 994 FWCI119.053

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

article Full Text OpenAlex 867 FWCI94.6127

Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity

article Full Text OpenAlex 863 FWCI245.6252

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity

article Full Text OpenAlex 849 FWCI132.5454

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

article Full Text OpenAlex 787 FWCI122.866

Obesity Management in Adults

review Full Text OpenAlex 755 FWCI37.4955